| Name | Title | Contact Details |
|---|---|---|
Lucas Donigian |
Vice President, Head of Business Development and Commercial | Profile |
Bijal Desai |
Vice President of Finance and Strategy | Profile |
Laura O`Connor |
Vice President of Human Resources and Diversity, Equity, and Inclusion | Profile |
Neil Klompas |
Chief Operating Officer and Chief Financial Officer | Profile |
Prem Girn |
Senior Director and Human Resources Business Partner | Profile |
Diosynth is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Organovo (NYSE MKT: ONVO) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, their technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and other outlets. Organovo is changing the shape of medical research and practice.
Acasti Pharma Inc. is an emerging biopharmaceutical company dedicated to the research, development and commercialization of innovative proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment, through a novel superior approach to lipid regulation. To carry out this mission, Acasti is advancing its portfolio of bioactive ingredients, by purifying and concentrating krill-oil extracts through innovative technology, to produce products targeting the prescription drug and medical food markets.
DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.
C4 Therapeutics is pioneering a new class of drugs. C4`s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.